Navigation Links
Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharma's Fall Line Up!
Date:12/20/2007

NEW YORK, Aug. 10 /PRNewswire/ -- ExL Pharma is pleased to announce the fall conference line up which covers many of the leading issues that are impacting the pharmaceutical industry today. The events that are currently scheduled offer educational and networking opportunities for Clinical, Marketing, R&D, and Medical Affairs executives from large to small pharmaceutical, biotech and medical technology companies.

Listed below are details on some of the featured events and highlights from those conferences:

September 10-11th, Philadelphia, PA

3rd Clinical Performance Metrics & Benchmarking- Measuring and Improving

Clinical Performance to Maximize Efficiency

The 2007 Metrics event features 5 Case Study examples from Pfizer, Merck,

Allergan, Astrazeneca, and Sanofi-Aventis on different clinical

performance measurement applications.

September 13-14th, San Francisco, CA

6th Investigator-Initiated Trials- Ensuring Quality Studies through

Increased Collaboration,

Participate in the first ever IIT working group and help shape best

practices and form future guidelines.

September 24-25th, Annapolis, MD

3rd Merging EHR & eClinical Technologies- Implementing the Technology for

Convergence

This event features presentations from Pfizer, Allscripts, Johnson &

Johnson, HL7 and CDISC discussing strategies for integrating drug

development and healthcare IT.

October 22-24, Princeton, NJ

Digital Pharma- Accelerating to the Next Generation of Marketing with Web

2.0

Hear leading pharmaceutical companies such as Abbott, Wyeth and Bayer

discuss how they are taking full advantage of Web 2.0 marketing strategies

to communicate with consumers and physicians.

November 5-6th, Princeton, NJ

3rd Pharmaceutical Meeting Planners Summit- The Ideal Networking

Environment for Pharmaceutical Meeting Planners

This newly updated agenda features perspectives from 13 different

pharmaceutical speakers which will offer an ideal learning experience for

participants.

November 8-9th, Orlando, FL

3rd MSL Next Practices- Communicating MSL Value to Business Partners

The winner of the "Best Industry Wide MSL Meeting Award for 2006" is back

focusing on next practices to be taken by MSL teams in order to enhance

value. Speakers include participants from Amgen, Genentech, Novo-Nordisk

and more.

To view our full list of upcoming conferences and webinars and details on our expert speaking faculties or to REGISTER, Log onto: http://www.exlpharma.com.

*Please mention Registration Code: EPR89 when registering

About ExL

ExL Pharma, a division of ExL Events, Inc., is an emerging leader in developing innovative, educational events that serve the healthcare community and allied professionals. Behind our diverse conference portfolio, our experienced team conducts extensive market research and targeted outreach. The results translate into innovative, high-quality conference events designed to exceed the dynamic informational needs of the healthcare community.


'/>"/>
SOURCE ExL Pharma
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
2. ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
3. Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011
4. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
5. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
6. Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC
7. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
8. AMDL Expands Drug Distribution in China With Additional Agreement, Valued at $2.3 Million Annually
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. iCAD, Inc. Awarded Two Additional Patents for Its Computer-Aided Detection Technology
11. Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... ... 2017 , ... Baltimore biotech firm, PathSensors, announced that its ... developing and issuing recommendations to grow Maryland's biohealth industry and position the state ... , The recommendations are contained in a report from the Maryland ...
(Date:5/19/2017)... ... ... In response to the strong base of evidence supporting the use of ... of their Gait Trainer 3 with an Integrated Music Therapy option. This is the ... rehabilitating individuals with cerebral palsy, traumatic brain injury, stroke and Parkinson’s disease. , ...
(Date:5/18/2017)... ... May 16, 2017 , ... Clinical Supplies Management (“CSM”), a Great ... company continues to grow. CSM has doubled in size over the past six ... aggressive growth strategy. , Roger Gasper joins CSM as Chief Financial Officer. Roger ...
(Date:5/18/2017)... ... May 17, 2017 , ... USDM Life ... for the life sciences and healthcare industries, is honored that Jay Crowley ... Devices conference in Brussels, Belgium. , Crowley played a crucial role in the ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
Breaking Biology News(10 mins):